Nasdaq Beam News Today

Beam Therapeutics Inc. (NASDAQ:BEAM – Get Free Report) shares rose 4.7% during trading on Monday . The stock traded as high as $22.45 and last traded at $22.38. Approximately 76,700 shares changed hands during mid-day trading, a decline of 95% from the average daily volume of 1,433,598 shares. The stock had previously closed at $21.38. […]

Beam Therapeutics Inc. (NASDAQ:BEAM – Get Free Report) shares were down 6.6% during mid-day trading on Thursday . The stock traded as low as $20.84 and last traded at $21.23. Approximately 468,916 shares changed hands during trading, a decline of 67% from the average daily volume of 1,435,909 shares. The stock had previously closed at […]

Beam Therapeutics Inc. (NASDAQ:BEAM – Get Free Report) was the recipient of a large increase in short interest during the month of March. As of March 15th, there was short interest totalling 14,320,000 shares, an increase of 9.2% from the February 29th total of 13,110,000 shares. Based on an average daily volume of 1,420,000 shares, […]

Shares of Beam Therapeutics Inc. (NASDAQ:BEAM – Get Free Report) have earned an average recommendation of “Hold” from the thirteen research firms that are presently covering the company, Marketbeat Ratings reports. Eight equities research analysts have rated the stock with a hold rating and five have issued a buy rating on the company. The average […]

Beam Therapeutics (NASDAQ:BEAM – Get Free Report)‘s stock had its “outperform” rating restated by investment analysts at BMO Capital Markets in a research report issued on Wednesday, Benzinga reports. They presently have a $57.00 target price on the stock. BMO Capital Markets’ target price suggests a potential upside of 68.29% from the stock’s previous close. […]

Beam Therapeutics (NASDAQ:BEAM – Get Free Report) issued its quarterly earnings results on Tuesday. The company reported $1.73 EPS for the quarter, topping the consensus estimate of ($0.69) by $2.42, Briefing.com reports. Beam Therapeutics had a negative net margin of 35.09% and a negative return on equity of 16.90%. The firm had revenue of $316.20 […]

Beam Therapeutics (NASDAQ:BEAM – Get Free Report) posted its quarterly earnings results on Tuesday. The company reported $1.73 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.69) by $2.42, Briefing.com reports. The company had revenue of $316.20 million for the quarter, compared to analysts’ expectations of $34.16 million. Beam Therapeutics had […]

Beam Therapeutics (NASDAQ:BEAM – Get Free Report)‘s stock had its “outperform” rating reiterated by analysts at Wedbush in a note issued to investors on Tuesday, RTT News reports. They presently have a $57.00 price objective on the stock, up from their prior price objective of $48.00. Wedbush’s price objective would suggest a potential upside of […]

Beam Therapeutics Inc. (NASDAQ:BEAM – Get Free Report) fell 8.9% during mid-day trading on Tuesday . The company traded as low as $30.30 and last traded at $30.44. 405,654 shares traded hands during mid-day trading, a decline of 66% from the average session volume of 1,195,352 shares. The stock had previously closed at $33.40. Analysts […]

Capula Management Ltd bought a new stake in shares of Beam Therapeutics Inc. (NASDAQ:BEAM – Free Report) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund bought 38,100 shares of the company’s stock, valued at approximately $916,000. A number of other hedge […]